Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
45 Cards in this Set
- Front
- Back
drug development and approval rough stages |
starts with drug discovery or synthesis, understanding its mechanism, and development of a compound with enhanced selectivity and potency; in vitro studies; in vivo metabolism and safety in animals; phases 1, 2, 3 human trials and phase 4 post approval; costs 15-900M to reach market and 30% of those return their investment cost; 10% of US healthcare $$ are spent on prescription drugs; global market is 640B |
|
possible approaches to drug discovery |
ID of new drug target; rational design of a new drug; chemical modification of known molecule; screening of libraries of compounds; biotechnology and cloning; combine known drugs for additive or synergistic effects or reposition a known drug for a new use |
|
synthesis of novel chemical compounds derived from where |
plants (cardiac glycosides), animal tissues (heparin), microbial cultures (PCN G), human cell cultures (urokinase), genet technology (human insulin); increased insight into structure-activity relationships permits a more focused search for new compounds |
|
precilinical safety and toxicity testing |
all drugs are toxic at some dose; assess risk by identifying potential human toxicities; no effect dose, minimum, and median lethal doses; the chosen human test dose will be about 1/10 to 1/100 of the preclinical no effect dose; the complete precilinical toxicity studies and estimates of therapeutic index may take 2-6 years |
|
3 major confounding factors for transitioning the investigative drug to human evaluation |
variable natural history of most diseases which requires large number of subjects and long period of study; presence of other diseases and risk factors or need to obtain accurate histories and properly randomize groups; patient and observer bias so need to have single and double bind designs |
|
what does the FDA do |
oversees the drug evaluation process (safe and effective) and grants approval of new drug products; complete absence of risk is impossible to demonstrate; it is possible to identify most of the hazards and their frequency in the study population so safety is based on the nature and incidence of hazards compared with the hazard or nontherapy of the target disease |
|
what is an IND |
notice of claimed investigational exemption for a New Drug; it is filed when a drug is ready to be tested in humans; it contains composition, source, chemical and manufacturing info, animal data, proposed protocols, names of physicians who will conduct trials, and compilation of key data relevant to study in humans |
|
phase 1 clinical testing |
dose-effect relationship established in 25-30 healthy volunteers; the goal is to find the max tolerated dose and see if humans show significantly different responses from animals; trials are nonblind; many toxicities are detected and pharmacokinetic measurements of absorption, half life, and metabolism are made; see if effects on body functions observed in animals occur in humans |
|
phase 2 clinical testing |
therapeutic efficacy assessed in 100-200 pts with the relevant disease; single blind; placebo, positive control, test drug; assess safety, efficacy, dose, additional toxicities, pharmacokinetics; if benefit is evident and any toxicity is acceptably small then phase 3 is entered |
|
phase 3 clinical testing |
larger pt groups (1000s) to further establish safety and efficacy; comparison of the new drug with standard therapy; some toxicities may first become apparent here; double blind and crossover designs often used; these trials must be approved by institutional ethics committees (IRB); phases 1-3 take 4-6 yrs; most drugs are revealed to be unusable; about one drug survives for every 10,000 newly synthesized compounds (0.01%) so 1/10 that begin phase 1 makes it through phase 3 |
|
what happens after phase 3 |
the manufacturer may submit an NDA to the FDA who review it over the course of months to years; must show that preclinical and clinical data provide evidence for meeting safety and efficacy criteria and that product formulation meets quality control standards; following approval to market the drug phase 4 begins |
|
phase 4 |
regulatory surveillance continues in the form of post licensing studies; monitoring of safety under actual conditions of use in very large numbers of pts; low incidence effects are usually not detected prior to phase 4; this is the only way to assess the long term risk benefit ratio and true therapeutic value; cost benefit evaluation may also be warranted for drugs with little benefit over older ones; adverse reactions in susceptible populations include tolerance, idiosyncracy (genetic origin), and allergy (immunologically mediated); during phase 4 serious and unexpected events (overdose, accident, withdrawal, adverse effects not listed in labeling) must be reported to FDA within 15 days |
|
phase 4 patent expiration |
occurs 20 yrs after IND; since it takes about 5 years from IND to FDA approval of the NDA that leaves no more than 15 years of patent protection; after that any company can produce the drug, file an abbreviated NDA, demonstrate equivalence, and with approval market the drug as a generic product |
|
types of bonds and attractive forces pertinent to drug-receptor binding in order of decreasing bond strangth |
covalent (irreversible; least common), ionic (+/-), hydrogen (H-O), hhydrophobic interactions, van der walls (dipole interactions) |
|
characteristics of classical receptors |
span the membrane; amphipathic (have polar and nonpolar regions); alpha helices form the nonpolar transmebrane regions |
|
receptor characterization |
depends on ligand binding specificity; radioligands (labeled drugs) are used to obtain measures of receptor-bound and free drug; after equilibrium binding, receptor bound (LR) and free unbound (L) drug are separated; concentrations of bound ligand (LG) and free ligand (L) are determined |
|
Kd= |
[L] [R] / [LR] = k2/k1 = Kd; [L] and [LR] can be measured but [R] cannot; [R] = [RT] - [LR] so [LR] / [L] = [RT] / Kd - [LR]/Kd; another way to say this is that [bound]/[free] = [boundm]/Kd - [bound]/Kd which can then be graphed in what is known as a scatchard plot; don't really need to know this slide; know the smaller the Kd the higher the binding affinity (Kd is the dissociation constant= the concentration needed for 50% binding) |
|
scatchard plot |
[B/F] is the y axis and [B] is the x axis; slope = -1/Kd and x intercept = Bmax |
|
determination of specific binding |
[specific receptor binding] = [total binding - nonspecific binding] |
|
what is specific binding |
saturable high affinity binding |
|
what is nonspecific binding |
nonsaturable low affinity binding |
|
drugs acting at the call membrane produce transmembrane signals by regulating one or more of the following |
ligand gated ion channels (aka receptor-operated channels); G proteins and second messengers; transmembrane enzymes |
|
transmembrane signaling mechanisms |
ligand gated ion channels; G protein coupled receptors (GPCRs); ligand regulated transmembrane enzymes= receptor tyrosine kinases and cytokine receptors; intracellular actions (regulation of gene transcription) |
|
how to ligand gated ion channels work |
neurotransmitters GABA (A type), ACh (nicotinic), 5-HT (5-HT3), and EEAs (e.g. glu) bind in part to ligand gated channels; increased memrbane conductance occurs by the opening of gated channels for specific ions (Na+, K+, Ca2+) which then follow their electrochemical gradients |
|
how do G protein coupled receptors (GPCRs) work |
membrane receptors associated with G proteins, an effector enzyme, and diffusible second messengers; G proteins are inactive when GDP is bound and active when GTP is bound; G proteins consist of an alpha, a beta, and a gamma subunit; the alpha subunit interacts with the activated receptor, with GDP/GTP and with the effector enzyme (or channel); types of G proteins are Gs, Gi, Go, and Gq; so binding of drug (i.e. ligand) to receptor, then receptor activation of a G protein, then G protein regulation of an enzyme or ion channel, then change in the concentration of a second messenger |
|
the effector and second messenger in the calcium phosphoinositide pathway |
phospholipase C for the effector and calcium, DAG, and phosphoinositide for the second messenger |
|
the effector and second messenger in the cAMP transduction pathway |
adenylyl cyclase (AC) for the effector and cyclic AMP (cAMP) for the second messenger |
|
the cAMP second messenger system |
the linked G protein is either Gs or Gi depending on the receptor subtype; this is an important concept for their system= stimulation of the receptor will cause either enhanced AC activity or decreased AC activity depending on whether the receptor complex is associated with Gs or Gi; a given receptor subtype is linked to one or the other but a cell may express multiple receptor subtypes; activation of AC results in synthesis of the secondary messenger cAMP from ATP; cAMP activated protein kinase A |
|
cAMP dependent protein kinases are made up of what and what do they do |
aka protein kinase As; regulatory and catalytic subunits; catalytic subunits are inhibited when associated with the regulatory subunits; cAMP combines with the regulatory subunits to cause dissociation from catalytic subunits, allowing activation of enzymatic activity; cAMP binds to regulatory domains of PKA liberating the catalytic subunits, Ca/CaM binds to the regulatory domain of CaMKII resulting in exposure of the catalytic domain; DAG, Ca, and PS are involved in activation of PKC |
|
inactivation mechanisms in the cAMP pathway |
inactivation of G proteins (GTPase); inactivation of second messengers (phosphodiesterases for cAMP); inactivation of protein kinases by phosphatases |
|
calcium phosphoinositide second messenger system |
G protein linked, Gq; activation of phospholipase C results in hydrolysis of phosphotidylinositol-4,5-bisphosphate (PIP2) into 2 second messengers (diacylglycerl (DAG) and inositol-1,4,5-triphosphate (IP3)); DAG activated protein kinase C; IP3 mobilizes stored intracellular calcium |
|
norepinephrine stimulation of G proteins results in an increased intracellular concentration of calcium; this increase is not reversed by the extracellular calcium chelator EGTA; which of the following is the most likely source of the increased intracellular calcium concentration: a. ER b. golgi c. lysosome d. nucleus e. plasma membrane |
a. ER |
|
ligand regulated transmembrane enzymes: receptor tyr kinases= where does the drug bind, what is the effect, what agonists |
drug or hormone binds to extracellular domain; allosteric effect with dimerization and autophosphorylation of intracellular domains; phsophorylated form phosphorylated substrate proteins; agonists include insulin, EGF, PDGF, other growth factors |
|
ligand regulated transmembrane enzymes: cytokine receptors= where does the drug bind, what is the effect, what agonists |
drug or hormone binds to extracellular domain; allosteric effect with dimerization and autophosphorylation of tyr residues on intracellular domains; phosphorylated form phosphorylated JAK tyr kinases, which in turn phosphorylated 'signal transducers and activators of transcription' STAT molecules; agonists are growth hormone, interferon, erythropoietin, and other growth factors |
|
what is homologous desensitization |
affecting responses elicited only by the stimulated receptor |
|
what is heterologous desensitization |
acting on several receptors or on a pathway common to many receptors |
|
cytosolic receptors |
steroid hormones cross the cell membrane and bind to cytosolic receptors; the complex is transported to the nucleus and binds DNA sequences near the gene whose expression is to be regulated |
|
nuclear receptors |
thyroid hormone enters the cell and passively enters nucleus to bind its receptor (part of chromatin) |
|
which of the following most accurately describes the transmembrane signaling process involved in steroid hormone action? a. action on a membrane spanning tyrosine kinase b. activation of a G protein which activated or inhibits adenylyl cyclase c. diffusion into a cell and binding to an intracellular receptor d. opening of transmembrane channels |
c |
|
presynaptiv reuptake |
major mechanism for terminating action of the monoamine transmitters; some drugs interfere with this mechanism by blocking reuptake carriers (TCAs, cocaine); some drugs can cause release of stored transmitter (amphetamine) |
|
most transmitters are stored where |
in intracellular storage vesicles |
|
reserpine |
interferes with this mechanism and prevents storage causing depletion |
|
extracellular sites of action examples |
the antocoagulant heparin and its antagonist protamine; chelating agents EDTA, penicillamine, and dimercaprol bind toxic metals (lead, copper, and mercury); antacids; laxatives |
|
the ED50 |
the effective dose; the dose at which 50% of people have the desired effect |
|
the LD50 |
the lethal dose; the dose at which 50% of people die |